Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. van der Heijde D, et al. Among authors: zeng x. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788492 Free PMC article. Clinical Trial.
Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial.
Zhang P, Gong Y, Liu Z, Liu Y, Lin W, Li J, Wang M, Liu X, Fei Y, Chen H, Peng L, Li J, Zhou J, Shi Q, Zhang X, Shen M, Zeng X, Zhang F, Li Y, Zhao Y, Zhang W. Zhang P, et al. Among authors: zeng x. Int J Rheum Dis. 2019 Aug;22(8):1479-1488. doi: 10.1111/1756-185X.13633. Epub 2019 Jun 27. Int J Rheum Dis. 2019. PMID: 31245907 Free PMC article. Clinical Trial.
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
Su J, Li M, He L, Zhao D, Wan W, Liu Y, Xu J, Xu J, Liu H, Jiang L, Wu H, Zuo X, Huang C, Liu X, Li F, Zhang Z, Liu X, Dong L, Li T, Chen H, Li J, He D, Lu X, Huang A, Tao Y, Wang Y, Zhang Z, Wei W, Li X, Zeng X. Su J, et al. Among authors: zeng x. BioDrugs. 2020 Jun;34(3):381-393. doi: 10.1007/s40259-020-00408-z. BioDrugs. 2020. PMID: 32078145 Free PMC article. Clinical Trial.
A pilot study of tofacitinib for refractory Behçet's syndrome.
Liu J, Hou Y, Sun L, Li C, Li L, Zhao Y, Zeng X, Zhang F, Zheng W. Liu J, et al. Among authors: zeng x. Ann Rheum Dis. 2020 Nov;79(11):1517-1520. doi: 10.1136/annrheumdis-2020-217307. Epub 2020 May 27. Ann Rheum Dis. 2020. PMID: 32461206 Clinical Trial. No abstract available.
Can low-dose methotrexate reduce effusion-synovitis and symptoms in patients with mid- to late-stage knee osteoarthritis? Study protocol for a randomised, double-blind, and placebo-controlled trial.
Zhu Z, Yu Q, Leng X, Han W, Li Z, Huang C, Gu J, Zhao Y, Wang K, Li T, Mei Y, Xu J, Zhang Z, Hunter D, Cicuttini F, Zeng X, Ding C. Zhu Z, et al. Among authors: zeng x. Trials. 2020 Sep 16;21(1):795. doi: 10.1186/s13063-020-04687-3. Trials. 2020. PMID: 32938470 Free PMC article.
Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target.
Xiang Y, Wang Q, Li H, Duan X, Fang Y, Yang P, Li Q, Wu R, Huo Y, Shi X, Wu Z, Wang Y, Jiang N, Hsieh E, Li M, Tian X, Zeng X; Chinese Registry of Rheumatoid Arthritis co-authors. Xiang Y, et al. Among authors: zeng x. Int J Rheum Dis. 2020 Dec;23(12):1719-1727. doi: 10.1111/1756-185X.13996. Epub 2020 Oct 9. Int J Rheum Dis. 2020. PMID: 33034424
15,399 results
You have reached the last available page of results. Please see the User Guide for more information.